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Available online 16 June 2016Actinic keratosis (AK) is a keratinocyte intraepidermal neoplasia UV light–induced that frequently appears in
sun-exposed areas of the skin. Although historically AK was defined as “precancerous”, actually it is considered
as the earliest stage of squamous cell carcinoma (SCC) in situ. Since AKs can progress into invasive SCC, their
treatment is recommended. AKs rarely develop as a single lesion; usuallymultiple lesions commonly affect an en-
tire area of chronically actinic damaged skin. This has led to the concept of “field cancerization”, an area chroni-
cally sun-exposed that surrounds peripherally visible lesions, in which are individualized subclinical alterations.
One of the main principles endpoint in the management of AKs is the evaluation and the treatment of field
cancerization. In this view, in order to detect and quantify field cancerization, we employed a method based
on the topical application of methyl aminolevulinate (MAL) and the detection of the fluorescence emitted by
its metabolite Protoporphyrin IX (PpIX); then, considering the extension and the intensity of measured fluores-
cence, we create a score of field cancerization. The results show that patients underwent to daylight PDT had a
reduction of total score, from T0 to T2. Whereas in the group untreated we observed a stability of total score or
a slightly worse. So, themethod and the score used allows to evaluate with a good approximation the dimension
of field cancerization and show the modification of it after treatment.







Actinic keratosis (AK) is a common UV light–induced cutaneous
lesion that results from the proliferation of atypical epidermal
keratinocytes. The incidence of development of AK in Caucasian popula-
tion increases with age, proximity to the equator and outdoor occupa-
tion. Australia has the highest skin cancer rate in the world. AKs are
discovered in up to 40–50% of the Australian population older than
40 years. Although historically AK was defined as “precancerous” or
“premalignant”, in agreement with recent histopathologic and molecu-
lar studies it is considered as the earliest stage of squamous cell carcino-
ma (SCC) in situ [1–4]. Transformation of AK into invasive SCC happens
following three progressive stages of keratinocyte intraepidermal neo-
plasia (KIN); in particular, KIN I and KIN II are characterized bya Interna e Specialità mediche
chool, V. le del Policlinico 155,proliferation of atypical keratinocytes in the epidermis lower third and
in the lower two-third respectively, while KIN III is characterized by
the presence of atypical keratinocytes in all layers of the epidermis. So,
all AK lesions, regardless of intraepidermal neoplasia thickness, are
potentially invasive [1] In according with the literature, the risk of pro-
gression of a single AK to an invasive SCC ranges from 0.25% to 20% per
year and up to 60% of invasive squamous cell carcinoma arose from AKs
[5–6]. Themain risk factors for the development of AKs include: fair skin
(Fitzpatrick type 1 or 2), old age, immunosuppressive therapy, PUVA-
therapy and arsenic exposure. The most important cause of AK forma-
tion is UV-B radiation (wavelength 315–280 nm) and UV-A radiation
(400–315 nm) from sun-light, in fact AKs are typically seen on fair-
skinned people in chronic sun-exposed areas and their frequency corre-
lates with cumulative UV exposure. The main mechanisms of AKs for-
mation are genetic mutations which cause proliferation of altered
keratinocytes, oxidative stress, immunosuppression, and altered apo-
ptosis due to dysregulation of p53 pathways [5]. Clinically AKs appears
at begin like small, rough spots that are easier felt than felt; afterwards
the lesions enlarge, usually becoming red and scaly, often covered by
yellow or brown adherent scales. Most lesions are only 3–10 mm, but
Fig. 1. Probe circular area.
Fig. 2. Fluorescence scale.
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trophic form, the lesions show little or no infiltration. The surrounding
areas may show evidence of widespread chronic sun damage with tel-
angiectasia and yellowish discoloration [7]. Histologically AKs is charac-
terized by dysplasia and architectural disorder of the epidermis, such as:
abnormal keratinocytes of the basal layer with nuclear atypia, altered
cellular polarity, hyperkeratosis and parakeratosis of the epidermis; an
irregular acanthosis may be present [5]. Since AKs can progress into in-
vasive SCC, their treatment is recommended. Approaches to AK can be
broadly divided into lesion-directed (cryotherapy, laser therapy, sur-
gery and curettage), or field-directed (diclofenac 3%, imiquimod 5%, 5-
fluorouracil, ingenol mebutate, chemical peels and ALA/MAL + PDT)
[8]. Lesion-directed therapies are reserved for patients who have only
a few isolated lesions and no elevated risk for development of invasive
SCC. Field-directed therapies target both clinically visible lesions and
preclinical alterations in the normal appearing skin surrounding the le-
sions; because AK is a visible marker of more extensive damage caused
by chronic UV radiation exposure, the REAKT Working Group recom-
mends field directed therapy as the optimal treatment approach for
most patients [9]. The apparently normal skin which surround lesions
is exposed to the same insults and could already reveal carcinoma-asso-
ciated genetic alterations; this area is known as the ‘field cancerization’.
The concept of “field cancerization” was introduced by Slaughter in
1953 [10]. In recentmolecular findings, it was established the following
definition of field cancerization: “the presence of one or more areas
consisting of epithelial cells that have genetic alterations. A field lesion
(or shortly ‘field’) has a monoclonal origin, and does not show invasive
growth andmetastatic behavior, the hallmark criteria of cancer.” A field
lesionmay have histological aberrations characteristic for dysplasia [11,
12]. The field cancerization is an area chronically sun-exposed that
surrounds peripherally visible lesions, in which are identified subclini-
cal alterations detectable through differentmethods: histologically,mo-
lecular biology, confocal microscopy and through fluorescence [12,13].
One of the main principles endpoint in the management of AKs is the
evaluation and the treatment of field cancerization. As the field
cancerization is, for its definition, a subclinical lesion, it is not possible
to recognize specific dermoscopy alterations, except those produced
by chronic sun damage (telangiectasia, epidermis atrophy and yellow-
ish discoloration, honeycomb pattern) [14]. Histologic features related
to field cancerization are epidermal atrophy, increased pigmentation
in basal keratinocytes, variable grade of atypia of basal keratinocytes,
multiple vascular ectasias in the superior dermis, loss of normal
keratinocyte polarization and intense degeneration of the dermic colla-
gen with solar elastosis [15]. The biopsy for the evaluation of the field is
invasive and not very useful, because it may not identify with precision
the field of cancerization. Reflectance confocal microscopy (RCM) is a
noninvasive imaging technique that allows the visualization of cellular
and subcellular structures of the skin in vivo with near histological res-
olution. It was postulated that initial changes of epidermal morphology
and cellular atypia may be observed by RCM before becoming clinically
apparent. Therefore, RCM may be useful for the evaluation of actinic
field cancerization and the detection of subclinical AK. The main fea-
tures observed at RCMare: at the level of the stratum spinosum, discrete
cellular and nuclear atypia of the keratinocytes, resulting in focal disrup-
tion of the epidermal architecture; at the level of the dermis, bright
irregular bundles were observed, suggestive of solar elastosis. Further-
more, small, branched, bright structuresmorphologically corresponding
to dilated blood vessels were seen [16]. Photodynamic therapy (PDT)
with topical application of 5-aminolevulinic acid (ALA) or its methyl
ester [methyl aminolevulinate (MAL)] as photosensitizers has proven
to be clinically effective in AKs, Bowen's disease and superficial basal
cell carcinoma (BCC) [17]. ALA orMAL ismetabolized in Protoporphyrin
IX (PpIX). All the cells own enzymes able to transform ALA to PpIX, al-
though the altered cells with increased rate of replication and metabo-
lism synthesize an excess of PpIX [18]. Preferential accumulation of
PpIX in altered skin is used to treat various skin diseases. As PpIX hasfluorescence properties, its preferential accumulation in altered cells
can be used as a marker of neoplastic keratinocytes. PpIX when excited
by blue light (408 nm) shows red fluorescence. So, the field of
cancerization could be identified by the detection of fluorescence emit-
ted by PpIX accumulated in the keratinocytes [19] and the degree of
fluorescence depends on the differential uptake of the photosensitizer
by neoplastic cells [20].
2. Materials and Methods
In this paper we provide a method based on the topical application
of MAL on AKs and perilesional areas and the successive detection of
the fluorescence emitted by its metabolite (PpIX), in order to evaluate
the score of field cancerization, considering the extension and the inten-
sity of the recordedfluorescence. Themethodwas applied to 20 patients
(10male and 10 female), affected by AKs on sun-exposed skin, aged be-
tween 58 and 80 years old with photo-type 2 and 3. The exclusion
criteria were: perilesional scarring and hypopigmentation, previous
treatment on AKs and immunosuppression. Moreover, we considered
as control group 10 patients not affected by clinically evident AKs,
applying MAL on not sun-exposed skin. We provide an example of
application and validity of this method for identifying the field
cancerization surrounding the lesions through the fluorescence emitted
by PpIX, a metabolite of MAL, which is a topical photosensitizer applied
at the level of altered skin with a cream formulation containing 16%
MAL (Metvix®). The choice of MAL is due to greater selectivity, reduced
time of occlusion and for the issuance of amore intense fluorescence for
greater formation of PpIX than ALA. In thefirst visit (T0), patients signed
the informed consent and have been subjected to clinical evaluation in
Table 1














1 79 Temple 22 41 63 21 23 44
2 65 Temple 18 24 42 10 11 21
3 71 Cheek 21 24 45 13 14 27
4 73 Nose 14 18 32 6 8 14
5 54 Scalp 14 16 30 5 5 10
6 71 Cheek 20 25 45 12 15 27
7 58 Scalp 10 17 27 4 6 10
8 66 Temple 20 22 42 9 11 20
9 78 Temple 20 43 63 21 23 44
10 70 Nose 12 19 31 7 7 14
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tographs of the affected areas, the lesions were examined using
Dermoscope FotoFinder®. Before the application of MAL, the patient's
areas were cleaned with alcohol in order to facilitate the penetration
of MAL; then, a 1 mm thin layer of cream with a concentration of
160 mg/g of MAL was accurately applied using wooden spatula on le-
sions and perilesional areas for an extension of 44 cm2. The treated
areas were occluded using a plastic film as the first layer, followed by
aluminum thin foil as the top layer, in order to avoid the early PpIX
formation by the daylight. After an occlusion period of 100–120 min,
the treated areas were uncovered and cleaned with gauze and saline
solution. Then, we photographed and recorded the fluorescence
intensity of PpIX emitted from the altered cells through the
FotoFinderFluorescence®, a probe testing an area of 44 cm2 and emit-
ting a wavelength between 340 nm and 420 nm. The pictures were ac-
quired at a fixed distance of 10 cm from the patient. In order to achieve
the highest fluorescence image quality while recording the images, all
light sources in the room except the Wood's lamp of the probe were
turned off or the probe was covered with dark cloth. The parameters
evaluated by this method were extension and intensity of fluorescence,
which is correlated with the intracellular concentration of PpIX. We di-
vided probe circular area, sizing 44 cm2, into eight equal sectors and
then split them at r = R/√2 into an inner circle and an external ring,
so that each of the sixteen half-sectors has the same area (Fig. 1).
For each sectors, we considered two parameters: Extension of fluo-
rescence (0 = absence of fluorescence, 1 = presence of fluorescence
in the central circle, 2 = presence of fluorescence in the perifericalTable 2






1 73 Cheek 20 24
2 58 Forehead 21 23
3 80 Temple 15 15
4 66 Temple 13 17
5 65 Forehead 14 14
6 74 Forehead 14 15
7 64 Cheek 6 16
8 65 Forehead 15 7
9 58 Temple 12 46
10 73 Temple 13 45
Table 3
Results of analysis for treated and untreated patients. From first column: mean and standard de
viation and minimum and maximum value of the variation normalized to the initial value.
b|ΔScore|N± σ ΔScore
Treated 18.90 ± 0.53 [17.00, 22.00]
Untreated 2.00 ± 0.47 [0.00, 5.00]circle) and Fluorescence Intensity (FI), established on the basis of scale
gradation of red (1: low FI, 2: moderate FI, 3 high FI and 4: very high
FI) (Fig. 2).
The total score is obtained adding the values of E and FI for each area
and adding all the partial results. So, the total score ranges from 2 to 88.
In order to evaluate the sensitiveness of the method, we divided the 20
patients into two groups. The first group composed of 10 patients was
treated with two sessions of daylight PDT at T0 and after one month
(T1), while in the second one patients was not treated and kept the
occlusion for 24 h with the aim to prevent the formation of PpIX. In
order to highlight modification of the field cancerization after the treat-
ment, patients come back to visit after three months (T2) and the score
was calculated the score by measuring the fluorescence through
FotoFinderFluorescence®.
In Table 1–2we show the collection of patient treated and untreated
respectively. The localization of field cancerization and the respective
parameter (extension, intensity and score) for both time T0 and T2 are
shown.
In Table 3we show the results of analysis, in particular themean and
standard deviation of the score variation (b|ΔScore|N ± σ) and of the
variation normalized to the initial value (b|ΔScore/Score(T0)|N ± σ),
as well as their minimum and maximum value.
3. Results
By a qualitative analysis, we observed a reduction of extension or in-








44 20 23 43
44 23 22 45
30 17 14 31
30 12 16 28
28 18 12 30
29 16 13 29
22 12 12 24
22 14 10 24
58 20 43 63
58 15 47 62
viation and minimum andmaximum value of the score variation, mean and standard de-
b|ΔScore/score(T0)|N± σ ΔScore/Score(T0)
0.48 ± 0.04 [0.30, 0.67]
0.06 ± 0.01 [0.00, 0.09]
Fig. 3. Fluorescence T0 in patient treated with PDT.
Fig. 4. Fluorescence T2 in patient treated with PDT.
Fig. 6. Graphic illustrating patients untreated for T0 and T2.
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T2 respectively. As can be seen in the Fig. 5, the patients of the first
group, treatedwith daylight PDT, had a reduction of the extension or in-
tensity of fluorescence, with a consequent reduction of total score.
In order to quantify this reduction, we compute the mean and stan-
dard deviation of variation ΔScore = |Score(T2)− Score(T0)| as listed
in Table 3. Patients treated had a decrease of the average b|ΔScore|N=
18.9. This value represents a significant b|ΔScore/Score(T0)|N = 48%
variation relative to score T0, and a nontrivial factor 40 in units of stan-
dard deviation σ= 0.5.
On the contrary in the group untreated Fig. 6 we observed a stability
of total score (b|ΔScore|N=2.0, b|ΔScore/Score(T0)|N=6% and a factor
4 in units of standard deviation σ= 0.5).
In the control group the observation with Wood light showed a
green fluorescence, that is expression of a non-pathological fluores-
cence, compatibly with skin without actinic damage.Fig. 5. Graphic illustrating patients treated with daylight PDT for T0 and T2.4. Discussion
In this studywe evaluated the effectiveness of a real-time, non-inva-
sive method finalized to highlight the field cancerization based on fluo-
rescence emitted by PpIX, a metabolite of MAL which is applied at the
level of the skin altered. In addition to MAL's known therapeutic uses,
the fluorescence emitted from its metabolite (PpIX) can be used as
method to detection an area macroscopically and histologically normal
but molecularly altered. For this purpose, we elaborated a score for
quantification of field which could be useful not only in the diagnostic
phase, but also for evaluate therapeutic response. The validity of the
method is confirmed by the significant reduction (b|ΔScore/T0|N =
48%) of the score in patients treated with PDT and the lack of its signif-
icant variation in untreated patients (b|ΔScore/Score(T0)|N= 6%). An
important element that emerged from our study is the greater expan-
sion of the field of cancerization than 25 cm2 that are usually considered
in the treatment field-directed.5. Conclusion
Ourmethod and the obtained score allows to evaluate noninvasively
andwith a good approximation the dimension of field cancerization and
enables to verify its consequent disappearance or reduction after the
treatment field-directed. The usual employment of the method could
be useful to evaluate the efficacy of new drugs in clinical trial which
have as endpoint their therapeutic activity on the field. Obviously the
sensibility of themethod could be not be comparedwith that of histopa-
thology in the discrimination between SCC in situ and invasive SCC. At
the best of our knowledge, this is the first study that propose the
creation of a score for the individuation and evaluation of severity and
extension of field of cancerization.
Nevertheless, the potential applicability of fluorescence in the
detection and quantification of field cancerization requires further
investigations.References
[1] Fernández-Figueras MT1, C. Carrato, X. Sáenz, L. Puig, E. Musulen, C. Ferrándiz, A.
Ariza, Actinic keratosis with atypical basal cells (AK I) is themost common lesion as-
sociated with invasive squamous cell carcinoma of the skin, J. Eur. Acad. Dermatol.
Venereol. 29 (5) (2015) 991–997 (May).
[2] B.A. Lober, C.W. Lober, Actinic keratosis is squamous cell carcinoma, South. Med. J.
93 (7) (2000) 650–655.
[3] B.A. Ackerman, Solar keratosis is squamous cell carcinoma, Arch. Dermatol. 139 (9)
(2003) 1216–1217.
[4] I. Zalaudek, S. Piana, E. Moscarella, et al., Morphologic grading and treatment of fa-
cial actinic keratosis, Clin. Dermatol. 32 (1) (2014) 80–87.
[5] J. Roewert-Huber, E. Stockfleth, H. Kerl, Pathology and pathobiology of actinic
(solar) keratosis - an update, Br. J. Dermatol. 157 (Suppl. 2) (2007) 18–20 (Dec.,
Medline).
76 A. Rossi et al. / Journal of Photochemistry & Photobiology, B: Biology 162 (2016) 72–76[6] R. Marks, G. Rennie, T.S. Selwood, Malignant transformation of solar keratoses to
squamous cell carcinoma, Lancet 1 (1988) 795–797.
[7] R. Anadolu-Brasie, A.R. Patel, S.S. Patel, et al., Squamous Cell Carcinoma of the Skin,
McGraw-Hill, 2008.
[8] A. Dodds, A. Chia, S. Shumack, Actinic keratosis: rationale and management,
Dermatol. Ther. 4 (1) (2014) 11–31 (Heidelb.).
[9] G. Hofbauer, M. Anliker, W.H. Boehncke, et al., Swiss clinical practice guidelines on
field cancerization of the skin, Swiss Med. Wkly. 24 (144) (2014) w14026.
[10] D.P. Slaughter, H.W. Southwick, W. Smejkal, Field cancerization in oral stratified
squamous epithelium, Cancer 6 (5) (1953) 963–968.
[11] B.J. Braakhuis, M.P. Tabor, J.A. Kummer, C.R. Leemans, R.H. Brakenhoff, A genetic ex-
planation of Slaughter's concept of field cancerization: evidence and clinical impli-
cations, Cancer Res. (2003).
[12] E. Stockfleth, C. Ferrandiz, J.J. Grob, I. Leigh, H. Pehamberger, H. Kerl, Development of
a treatment algorithm for actinic keratoses: a European Consensus, Eur. J. Dermatol.
(2008).
[13] B.J. Braakhuis, C.R. Leemans, R.H. Brakenhoff, Expanding Fields of Genetically Altered
Cells in Head and Neck Squamous Carcinogenesis, Semin, Cancer Biol, 2005.[14] L.A. Ribeiro Torezan, C. Festa-Neto, Cutaneous Field Cancerization: Clinical, Histo-
pathological and Therapeutic Aspects, An. Bras, Dermatol, 2013.
[15] J.A. Reed, C.R. Shea, LentigoMaligna: Melanoma in Situ on Chronically Sun-damaged
Skin, Arch. Pathol. Lab, Med, 2011.
[16] M. Ulrich, D. Krueger-Corcoran, J. Roewert-Huber, W. Sterry, E. Stockfleth, S. Astner,
Reflectance confocal microscopy for noninvasive monitoring of therapy and detec-
tion of subclinical actinic keratosis, Dermatology (2010).
[17] M.C. Almeida Issa, M. Manela-Azulay, Photodynamic Therapy: A Review of the Liter-
ature and Image Documentation, An. Bras, Dermatol, 2010.
[18] B.W. Henderson, T.J. Dougherty, How Does Photodynamic Therapy Work?
Photochem, Photobiol, 1992.
[19] P. Babilas, S. Schreml, M. Landthaler, Rolf-Markus Szeimies, Photodynamic Therapy
in Dermatology: State-of-the-art, Photodermatology, Photoimmunology &
Photomedicine, 2010.
[20] J.P. Ortonne, G. Gupta, N. Ortonne, L. Duteil, C. Queille, P. Mallefet, Effectiveness of
cross polarized light and fluorescence diagnosis for detection of subclinical and clin-
ical actinic keratosis during imiquimod treatment, Exp. Dermatol. (2010).
